nasdaq 100 component s & p 500 component industry biotechnology founded 1986 headquarters summit new jersey u.s. key people robert j. hugin executive chairman sol j. barer founder mark alles ceo products thalomid revlimid revenue us 6.4939 billion 2013 1 us 5.5067 billion 2012 1 operating income us 1.8089 billion 2013 1 us 1.7464 billion 2012 1 net income us 1.4499 billion 2013 1 us 1.4562 billion 2012 1 total assets us 13.3782 billion 2013 2 us 11.7343 billion 2012 1 total equity us 5.5899 billion 2013 1 us 5.6945 billion 2012 1 number of employees 4 182 december 2010 3 website www.celgene.com celgene corporation is an american biotechnology company that manufactures drug therapies for cancer and inflammatory disorders . it is incorporated in delaware and headquartered in summit new jersey . the company s major products are thalomid thalidomide which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma and revlimid lenalidomide for which the company has received fda and ema approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy . revlimid is also approved in the united states for the treatment of patients with transfusion dependent anemia due to low or intermediate 1 risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities . both thalomid and revlimid are sold through proprietary risk management distribution programs to ensure safe and appropriate use of these pharmaceuticals . vidaza is approved for the treatment of patients with mds . celgene also receives royalties from novartis pharma ag on sales of the entire ritalin family of drugs which are widely used to treat attention deficit hyperactivity disorder adhd . celgene cellular therapeutics a subsidiary is a public cord blood bank . contents 1 history 1.1 specialty pharmacy 1.2 acquisition history 2 products 3 litigation 3.1 anti trust allegations 4 see also 5 references 6 external links history edit in 1986 celgene originally a unit of the celanese corporation was spun off as an independent company following the merger of celanese corporation with american hoechst corporation . in july 1998 celgene received approval from the fda to market thalamid for the acute treatment of the cutaneous manifestations of moderate to severe enl . in april 2000 celgene reached an agreement with novartis pharma ag to license d mph celgene s chirally pure version of ritalin . the fda subsequently granted approval to market d mph or focalin in november 2001 . in august 2000 celgene acquired signal pharmaceuticals inc. a privately held company that searches for and develops pharmaceuticals that regulate disease related genes . signal pharmaceuticals inc. now operates as celgene research san diego a wholly owned subsidiary of celgene corporation . in december 2002 celgene acquired anthrogenesis a privately held new jersey based biotherapeutics company and cord blood banking business which is developing technology for the recovery of stem cells from placental tissues following the completion of full term successful pregnancies . anthrogenesis now operates as celgene cellular therapeutics a wholly owned subsidiary of celgene . in december 2005 celgene received approval from the fda to market revlimid for the treatment of patients with transfusion dependent anemia due to low or intermediate 1 risk mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities . in may 2006 celgene received approval for thalamid in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma . in june 2007 celgene received full marketing authorization for revlimid in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy by the european commission . in march 2008 celgene closed its 2.9 billion acquisition of pharmion corporation . in december 2009 celgene announced the acquisition of gloucester pharmaceuticals . 4 in june 2010 celgene corporation and abraxis bioscience inc. jointly announced the signing of a definitive merger agreement in which celgene has agreed to acquire abraxis bioscience . 5 in 2010 celgene looked to relocate its uk headquarters from riverside house in windsor to a new development stockley park uxbridge . 6 in january 2012 celgene and avila therapeutics inc. a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing announced a definitive merger agreement under which celgene corporation will acquire avila therapeutics inc. under the terms of the merger agreement celgene will acquire avila therapeutics inc. for 350 million in cash plus up to 195 million for milestones contingent upon the development and regulatory approval of avl 292 as well as up to 380 million in potential milestone payments contingent upon the development and approval of candidates generated from the avilomics platform . 7 citing a market capitalization of us 67 billion and stock appreciation of 107 % celgene was forbes magazine s number 2 ranked drug company of 2013 . 8 in 2014 celgene and oncomed pharmaceuticals entered into a cancer stem cell therapeutic development agreement encompasing demcizumab and five other biologics from onomed s pipeline . 9 also in 2014 sutro biopharma entered into a strategic collaboration and option agreement with celgene corporation to discover and develop multispecific antibodies and antibody drug conjugates adcs . this new agreement follows the december 2012 collaboration between the two companies and focuses on the field of immuno oncology while further broadening the sutro platform for discovery development and manufacture of best in class biotherapeutics . 10 in april 2015 celgene announced it would commence a collaboration with astrazeneca worth 450 million studying their phase iii immuno oncology drug candidate medi4736 . 11 later in the same month celgene announced it would acquire quanticel for up to 485 million aimed at enhancing their cancer drug pipeline through quanticels epigenetic modifier targeting applications . 12 in june 2015 celgene announced it had licensed lyceras rorgamma agonist portfolio for up to 105 million and continue to develop its phase i lead compound lyc 30937 for the treatment of inflammatory bowel disease . the licensing opportunity gives celgene the option to acquire lycera . 13 in july 2015 the company announced it would acquire receptos for 7.2 billion in a move to strengthen the company s inflammation and immunology areas . 14 news of the deal sent celgene shares up 5.7 % in after hours trading . in may 2016 the company announced it would launch partnership with agios pharmaceuticals developing metabolic immuno oncology therapies . the deal could net more than 1 billion for agios . 15 specialty pharmacy edit in 2006 celegene certified mckesson specialty a specialty pharmacy as one of a select group of revassist sm program contract pharmacies to launch lenalidomide trade name revlimid . as a specialty drug lenalidomide requires special handling and is therefore only available through the revassist program a unique distribution network employing only certified contracted specialty pharmacies . 16 acquisition history edit the following is an illustration of the company s major mergers and acquisitions and historical predecessors this is not a comprehensive list celgene receptos acq 2015 quanticel acq 2015 avila therapeutics inc acq 2012 abraxis bioscience inc acq 2010 gloucester pharmaceuticals acq 2009 pharmion corporation acq 2008 anthrogenesis acq 2002 signal pharmaceuticals inc acq 2000 celgene spun off from celanese in 1986 products edit product portfolio brand name drug name s indication date approved usa 17 partner vidaza azacitidine treatment of patients with refractory anemia chronic myelomonocytic leukemia 05 19 2004 revlimid lenalidomide transfusion dependent anemia due to low or intermediate 1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities 12 27 2005 revlimid lenalidomide in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy 06 29 2006 thalomid thalidomide acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl and maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrences 07 16 1998 thalomid thalidomide in combination with dexamethasone treatment of patients with newly diagnosed multiple myeloma 05 25 2006 glaxosmithkline alkeran melphalan palliative treatment of multiple myeloma and for the palliation of non resectable epithelial carcinoma of the ovary 01 17 1964 glaxosmithkline alkeran melphalan hydrochloride the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate 11 18 1992 glaxosmithkline focalin dexmethlyphenidate hydrochloride cii attention deficit hyperactivity disorder adhd in children and adolescents 11 13 2001 novartis focalin xr dexmethlyphenidate hydrochloride cii attention deficit hyperactivity disorder adhd in children adolescents and adults 05 26 2005 novartis litigation edit anti trust allegations edit in 2009 dr. reddy s laboratories requested and celgene refused to provide a samples of celgene s anticancer drug thalomid thalidomide . dr. reddy s laboratories sought the material for bioequivalency studies required to bring its own generic version of thalidomide to market . in response to the refusal dr. reddy s laboratories filed a citizen s petition with the fda asking the agency to adopt procedures that would ensure generic applicants the right to buy sufficient samples to perform bioequivalence testing of drugs that were subject to rems distribution restrictions . celgene denied that it had behaved anticompetitively arguing that the legislative history strongly suggested that congress considered and rejected a proposed guaranteed access procedure like the one proposed by dr. reddy s. celgene further argued that requiring innovator companies to sell their products to potential generic competitors would violate its intellectual property rights and subject it to liability risks in the event that patients were harmed in dr. reddy s studies . generic manufacturer lannett company initiated antitrust litigation that accused celgene of using its rems for thalomid thalidomide to violate the anti monopolization provisions of the sherman act . in early 2011 the district court denied celgene s motion to dismiss . the case was set for trial beginning in february 2012 but the parties settled before the trial began thereby postponing further judicial review of antitrust claims premised on alleged abuse of rems distribution restrictions . 18 see also edit companies portal pharmaceutical industry in switzerland sutro biopharma references edit a b c d e f g h i celgene corp de 2013 annual report form 10 k xbrl . united states securities and exchange commission . february 13 2014 . celgene corp de 2014 q1 quarterly report form 10 q xbrl . united states securities and exchange commission . april 29 2014 . 2010 form 10 k celgene corporation . united states securities and exchange commission . celgene to acquire gloucester pharmaceuticals dec. 7 2009 celgene to acquire abraxis bioscience inc. jun. 30 2010 new head quarters for celgene stockley park greets new tenant . uk construction magazine . 13 october 2011 . check date values in date help pdf http www.avilatx.com news 2012 0126 avilacelgene.pdf . missing or empty title help grading pharma in 2013 . forbes . december 31 2013 . staff january 1 2014 . oncomed celgene in 3.3 b cancer stem cell collaboration . industry watch . gen. eng . biotechnol . news . p. 8 . sutro biopharma and celgene corporation enter multi year strategic collaboration and option to acquire agreement . gen news highlights astrazeneca inks 1.8 b in immuno oncology deals as q1 profit dips . gen. gen news highlights celgene to acquire quanticel for up to 485m . gen. celgene licenses lycera s immune modulators in up to 105m deal . gen. celgene to acquire receptos for 7.2 b . gen. celgene agios launch 1b metabolic immuno oncology alliance gen news highlights gen . gen. celgene selects mckesson specialty as a revassist program pharmacy vendor to launch revlimid mckesson specialty to provide dispensing reimbursement and clinical services prnewswire harahan la . 13 february 2006 retrieved 5 november 2015 drugs fda fda approved drug products . food and drug administration .